BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20170101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20170101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180409
DTEND;VALUE=DATE:20180411
DTSTAMP:20260515T074216
CREATED:20171106T103751Z
LAST-MODIFIED:20171107T020509Z
UID:3819-1523232000-1523404799@www.pharmajournalist.com
SUMMARY:Digital Pharma Japan
DESCRIPTION:The inaugural Digital Pharma Japan conference will deliver a world class event for Japanese pharmaceutical and medical device executives to learn how to embed a digital ecosystem that is tailored for execution specifically in the Japanese business model. \n  \nTo learn more about this event\, and to register online\, visit http://digitalpharmaseries.com/japan
URL:https://www.pharmajournalist.com/event/digital-pharma-japan/
LOCATION:The Westin Tokyo\, 1-4-1 Mita Meguro-ku\, Tokyo\, Tokyo 153-8580\, Japan
ORGANIZER;CN="ExL Events":MAILTO:digitalpharma@exlevents.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180409
DTEND;VALUE=DATE:20180411
DTSTAMP:20260515T074216
CREATED:20171109T010959Z
LAST-MODIFIED:20171109T011019Z
UID:3890-1523232000-1523404799@www.pharmajournalist.com
SUMMARY:10th annual Adaptive Designs in Clinical Trials
DESCRIPTION:Now running for 10 years\, SMi’s annual conference on Adaptive Designs in Clinical Trials will return to London on 9th and 10th April 2018. \n \nThis year’s agenda has been curated to provide you with the latest innovations\, regulatory updates\, and strategies on how industry and clinical experts are currently using adaptive designs in their clinical trials for successful drug\, medical device and therapy development. \nGiving you a fresh take on this vital area of biopharma\, the event will ride the wave of technology within the pharmaceutical industry\, as we consider how the increasing use of smartphone apps and digital devices is changing the way trials run. Simultaneously\, the event will also explore how adaptive designs are being used for the production of personalised medicines and personalised therapies. \n  \nFeatured Speakers include: \n– James Matcham\, Head of Biometrics\, Early Clinical Development\, AstraZeneca\n– Alex Sverdlov\, Director\, Statistical Scientist\, Novartis\n– Frank Fleisher\, Principal Methodology Statistician\, Boehringer-Ingelheim\n– Christine Fletcher\, Executive Director Biostatistics\, Amgen\n– Chris Harbron\, Principal Statistical Scientist\, Roche\n– Olivier Collignon\, Biostatistician\, European Medicines Agency\n– Beatrice Panico\, Medical Advisor\, MHRA\n– Corine Baayen\, Senior Biostatistician\, H.Lundbeck \nKey Highlights \n– Explore the current industry outlook and evaluate the promises and challenges of digital technology use\n– Hear exciting case studies on enrichment designs and group sequential trials\n– Discover how big pharma companies are using Platform Trials and self-adapting priors to advance their adaptive clinical trials\n– Examine the use of adaptive clinical trials are used to produce targeted therapies\n– Learn from the latest regulatory perspectives from MHRA and EMA\, including planning and assessing umbrella and basket trials \nEarly Bird: Book by Dec 15 to save £400. Book by Jan 31 to save £200. Book by 28 Feb to save £100. \nTo learn more about this event\, and to register online\, visit http://www.adaptivedesigns.co.uk/pharmajournalist
URL:https://www.pharmajournalist.com/event/10th-annual-adaptive-designs-clinical-trials/
LOCATION:Copthorne Tara Hotel\, London\, UK
ORGANIZER;CN="SMi Group Ltd":MAILTO:hdegracia@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180409
DTEND;VALUE=DATE:20180411
DTSTAMP:20260515T074216
CREATED:20180115T131419Z
LAST-MODIFIED:20180115T131741Z
UID:7654-1523232000-1523404799@www.pharmajournalist.com
SUMMARY:Antibodies & Antibody Drug Conjugates
DESCRIPTION:SMi is proud to present their 6th annual Antibodies and Antibody Drug Conjugates conference\, being held at the Copthorne Tara Hotel\, London\, UK on the 9th – 10th April 2018.With an every-growing industry\, the market is expected to reach USD 30 Billion by 2023.www.adcsummit.com/pjl \nAntibodies and antibody drug conjugates (ADCs) have the potential to make a ground-breaking impact upon medicinal therapies\, diagnostics and characterization of diseases. There is massive potential for ADCs to be used in the development of targeted solid tumour therapies\, due to their ability to act as precisely and effectively on target antigens. \nJoin us this April 2018\, as SMi’s ADC Summit conference brings together industry experts from leading life science and pharmaceutical companies. Key topics that will be covered in the upcoming event include: fragment drug conjugates\, ADC payloads\, site-selective ADCs/ site-specific conjugation and the best linker and warhead combinations. \nHow Will You Benefit? \nNetwork and learn from leading professionals such as: \nChairs for 2018: \n– MahendraDeonarain\, Chief Executive and Scientific Officer\, Antikor Biopharma\n– Rakesh Dixit\, Vice President and Global Head Biologics Safety Assessment\, Medimmune \nKey Speakers Include: \n– Robert Lyon\, Senior Director\, Seattle Genetics\n– Arnaud Tiberghien\, Scientist II\, Spirogen\n– Alison Betts\, Associate Research Fellow\, Pfizer\n– Thomas Pillow\, Senior Scientist\, Genentech\n– Andreas Pahl\, CSO\, Heidelberg Pharma\n– Carlo Boutton\, Director of Technology\, Ablynx \nSome Featured Highlights will include: \n– Learn about the implementation of superior technologies to develop more effective and efficient Antibody Drug Conjugates.\n– Discover new and novel payloads\, e.g. Antibody Targeted Amanitin Conjugates (ATACs) and minorgroove binding DNA-interactive molecules as ADC payloads\, to expand the ADC landscape.\n– Discuss the practicalities of the use of Highly Potent Active Pharmaceutical Ingredients.\n– Refine the practice of using fragment conjugates in order to develop a tailored therapy for solid tumours.\n– Design principles for maximising the drug delivery efficiency and therapeutic index. \nView the full agenda: www.adcsummit.com/pjl
URL:https://www.pharmajournalist.com/event/antibodies-antibody-drug-conjugates/
LOCATION:Copthorne Tara Hotel\, London\, UK
ORGANIZER;CN="SMi Group Ltd":MAILTO:psolanki@smi-online.co.uk
END:VEVENT
END:VCALENDAR